Stockscreener 앱 받기
72.73
2.28%
-1.70
시간 외 거래:
72.73
전일 마감가:
$74.43
열려 있는:
$74.14
하루 거래량:
1.25M
Relative Volume:
1.45
시가총액:
$3.31B
수익:
$1.33B
순이익/손실:
$97.31M
주가수익비율:
35.80
EPS:
2.0317
순현금흐름:
$260.44M
1주 성능:
-7.70%
1개월 성능:
+29.21%
6개월 성능:
-9.06%
1년 성능:
+5.39%
1일 변동 폭
$72.50
$74.89
1주일 범위
$72.50
$81.99
52주 변동 폭
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
명칭
Haemonetics Corp
전화
(781) 848-7100
주소
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
72.73 | 3.50B | 1.33B | 97.31M | 260.44M | 2.0317 |
ABT
Abbott Laboratories
|
88.50 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.14 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.14 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.95 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.68 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 다운그레이드 | Needham | Buy → Hold |
| 2025-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-08-11 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | 재확인 | Barrington Research | Outperform |
| 2025-08-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-07-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-06-26 | 개시 | Robert W. Baird | Outperform |
| 2025-02-07 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-12-06 | 개시 | JP Morgan | Overweight |
| 2024-11-08 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | 개시 | CL King | Buy |
| 2024-09-11 | 개시 | BofA Securities | Neutral |
| 2024-09-10 | 개시 | BTIG Research | Buy |
| 2024-06-12 | 업그레이드 | Needham | Hold → Buy |
| 2022-10-13 | 개시 | Mizuho | Buy |
| 2022-01-27 | 다운그레이드 | Needham | Buy → Hold |
| 2021-12-15 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-08-17 | 재개 | Raymond James | Outperform |
| 2021-06-17 | 개시 | Citigroup | Buy |
| 2021-05-14 | 업그레이드 | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | 다운그레이드 | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | 업그레이드 | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | 개시 | Needham | Buy |
| 2019-08-07 | 재확인 | Barrington Research | Outperform |
| 2019-05-14 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | 재확인 | Barrington Research | Outperform |
| 2018-08-09 | 재확인 | Barrington Research | Outperform |
| 2018-02-07 | 재확인 | Barrington Research | Outperform |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | 재확인 | Barrington Research | Outperform |
| 2017-08-08 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | 재확인 | The Benchmark Company | Hold |
| 2016-09-20 | 다운그레이드 | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | 다운그레이드 | Sidoti | Buy → Neutral |
| 2016-08-02 | 재확인 | Jefferies | Buy |
| 2016-08-02 | 재확인 | The Benchmark Company | Hold |
모두보기
Haemonetics Corp 주식(HAE)의 최신 뉴스
HAE Maintained by Mizuho -- Price Target Raised to $85.00 - GuruFocus
Mizuho raises Haemonetics stock price target to $85 on plasma demand - Investing.com UK
HAE SEC FilingsHaemonetics Corp Mass 10-K, 10-Q, 8-K Forms - Stock Titan
Is Haemonetics’ (HAE) Apheresis Reorg Quietly Redefining Its Competitive Edge in Medical Devices? - simplywall.st
HAEMONETICS CORP ($HAE) President and CEO 2026 Pay Revealed - Quiver Quantitative
[ARS] HAEMONETICS CORP SEC Filing - Stock Titan
Executive pay and equity plans in Haemonetics (NYSE: HAE) 2026 proxy filing - Stock Titan
A Look At Haemonetics (HAE) Valuation After Its New Apheresis And MedSurg Segment Realignment - Yahoo Finance
A Look at Haemonetics Corp (HAE) After 5.0% Gain -- GF Value $84 - GuruFocus
Haemonetics (NYSE: HAE) VP settles RSU taxes with 259 withheld shares - Stock Titan
Haemonetics (HAE) SVP has 313 shares withheld for RSU tax obligations - Stock Titan
Haemonetics Corp at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Haemonetics Corp stock (US4041191090): solid growth story in blood management and plasma technology - AD HOC NEWS
Is Haemonetics (HAE) Stock Price Reflecting Its Recent 29% Monthly Surge Accurately - simplywall.st
Haemonetics Corp stock (US4041191090): segment restructuring shifts focus to Apheresis and MedSurg - AD HOC NEWS
Haemonetics Restructures Business Segments for Enhanced Efficien - GuruFocus
Haemonetics Updates Financial Reporting Segments, Combines Plasma and Blood Center Into Apheresis, Renames Hospital to MedSurg 1 - Minichart
Haemonetics restructures reporting segments from three to two - Investing.com
Haemonetics updates reporting structure, combines Plasma and Blood Center into Apheresis - TradingView
Haemonetics (NYSE: HAE) consolidates business into new Apheresis and MedSurg segments - Stock Titan
Haemonetics Updates Financial Reporting Segments - PR Newswire
Haemonetics Corp (HAE) Shares Surge 6.0% -- What GF Score of 79 Tells Investors - GuruFocus
Haemonetics earnings ahead: Can vascular closure rebound? - Investing.com
Haemonetics stock falls from recent highs amid weekly seller pressure and overbought signals - Traders Union
Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference - PR Newswire
Haemonetics Corp stock (US4041191090): shares trade lower after recent pullback on NYSE - AD HOC NEWS
HAE Maintained by Citigroup -- Price Target Raised to $70 - GuruFocus
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Raises Target Price to $70 - 富途牛牛
Why Haemonetics NYSE Composite Earnings Sparked Attention? - Kalkine Media
Haemonetics' (NYSE:HAE) Conservative Accounting Might Explain Soft Earnings - simplywall.st
Why Haemonetics (HAE) Is Up 14.3% After Earnings Beat And BofA Upgrade And What's Next - Yahoo Finance
Is It Time To Reassess Haemonetics (HAE) After The Recent Share Price Jump - simplywall.st
Haemonetics (HAE) Stock Is Up, What You Need To Know - Yahoo Finance
Medical Devices & SuppliesSpecialty Stocks Q1 Highlights: Haemonetics (NYSE:HAE) - Yahoo Finance
Haemonetics (HAE) Upgraded to Buy by Bank of America, Target Pri - GuruFocus
HAE Upgraded by B of A Securities -- Price Target Raised to $80 - GuruFocus
Haemonetics (HAE) Upgraded to Buy by Bank of America, Shares Cli - GuruFocus
Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends - Yahoo! Finance Canada
This Texas Instruments Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday - Benzinga
BofA upgrades Haemonetics stock rating on conservative guidance - Investing.com
BofA upgrades Haemonetics stock rating on conservative guidance By Investing.com - Investing.com Canada
Is It Too Late to Buy Haemonetics Corp (HAE) After 4.0% Rally? G - GuruFocus
Does Haemonetics (HAE) Have Enduring Growth Potential? - Insider Monkey
Q3 2026 Haemonetics Corp Earnings Call Transcript - GuruFocus
Haemonetics Corp 2026 Annual Report: Business Overview, Market Segments, Products, and Competitive Landscape - Minichart
Haemonetics (NYSE: HAE) outlines segment shifts, major customers and risks - Stock Titan
Haemonetics (HAE) EVP and General Counsel receives 28,424 RSUs, 2,913 shares withheld for taxes - Stock Titan
[Form 4] HAEMONETICS CORP Insider Trading Activity - Stock Titan
Haemonetics (NYSE: HAE) CFO granted 29,312 RSUs with tax withholding - Stock Titan
Haemonetics (NYSE: HAE) VP granted 2,220 RSUs, 197 shares withheld for tax - Stock Titan
Haemonetics (HAE) EVP Roy Galvin granted RSUs as 879 shares withheld for taxes - Stock Titan
Haemonetics Corp (HAE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.43%
자본화:
|
볼륨(24시간):